CR | Jotup

Crane Company Announces Date for Third Quarter 2023 Earnings Release and Teleconference

Retrieved on:

Wednesday, October 4, 2023

Engineering, Chemicals, Plastics, Aerospace, Oil, Gas, Manufacturing, Energy, CR, CFO, NYSE, Crane Holdings, Management

Crane Company (NYSE: CR) announces the following schedule and teleconference information for its third quarter 2023 earnings release:

Key Points:

Crane Company (NYSE: CR) announces the following schedule and teleconference information for its third quarter 2023 earnings release:
Teleconference: October 24, 2023 at 10:00 AM (Eastern) hosted by Max H. Mitchell, President & CEO, and Richard A. Maue, Executive Vice President & CFO.
The call can be accessed in a listen-only mode via the Company’s website www.craneco.com .
An accompanying slide presentation will also be available on the Company’s website.
Web Replay: Will be available on the Company’s website shortly after completion of the live call.

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

Retrieved on:

Wednesday, October 4, 2023

SAN DIEGO, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that it plans to highlight new preliminary clinical and preclinical data from studies of nanatinostat and valganciclovir (Nana-val), its all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers, during an R&D Day today, Wednesday, October 4, 2023, at 8:00 a.m. EDT.

Key Points:

“The clinical responses and favorable safety profile observed in multiple relapsed or refractory EBV-positive lymphoma patient populations continue to be encouraging.
In addition, the R&D Day will feature presentations by expert key opinion leaders who will discuss the high unmet medical needs of EBV-associated lymphomas.
Enrollment completed through the fifth dose level of the Phase 1b dose escalation portion of the trial without any dose-limiting toxicities reported.
A live video webcast of the presentation will be available here and on the Investors section of the Viracta website under " Events and Webcasts ".

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

Retrieved on:

Tuesday, October 3, 2023

Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, CMC, NDA, Bladder cancer, Mitomycins, Malignancy, Patient, Chemistry, CR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, ATLAS, Pharmaceutical industry

The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls (CMC) sections of the NDA, which is planned for January 2024.

Key Points:

The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls (CMC) sections of the NDA, which is planned for January 2024.
“We are very pleased with the outcome of our pre-NDA meeting where the FDA agreed with our plan to submit our NDA for UGN-102 once all patients reach 12 months post CR.
Our dialogue with the FDA during our recent pre-NDA meeting was very constructive and underscores the strength of our clinical program for UGN-102,” said Liz Barrett, President and CEO, UroGen.
“With the announcement of positive Phase 3 topline results from the ATLAS and ENVISION studies earlier this year, this meeting was a significant step in defining the path forward for NDA submission and potential approval for UGN-102.

ITRI and University of Arts Linz Sign MOU to Combine Robotics R&D with Austria Artistic Energy

Retrieved on:

Tuesday, October 3, 2023

ITRI, Mirage, National Taiwan University of Arts, TM, Research, Multimedia, Science, Art, Build automation, MOU, CR, Robotics, University of Art and Design Linz, 3D printing

HSINCHU, Oct. 3, 2023 /PRNewswire/ -- ITRI has signed a Memorandum of Cooperation (MOU) with the University of Art and Design Linz (UfG Linz), paving the way for artist exchanges and laboratory cooperation projects between ITRI and Creative Robotics (CR), a research unit within UfG Linz dedicated to arts-based and industrial research on robotics.

Key Points:

HSINCHU, Oct. 3, 2023 /PRNewswire/ -- ITRI has signed a Memorandum of Cooperation (MOU) with the University of Art and Design Linz (UfG Linz), paving the way for artist exchanges and laboratory cooperation projects between ITRI and Creative Robotics (CR), a research unit within UfG Linz dedicated to arts-based and industrial research on robotics.
The MOU was inked with the assistance of a collaborative robot provided by Techman Robot, exemplifying the technological strength of Taiwan.
Erik Aigner, Vice Rector at UfG Linz, expressed his enthusiasm for future cooperation with the leading international research institute.
He emphasized the importance of technology and resource exchanges, aimed at facilitating innovative robotics applications at the crossroads of art, science, and industry.

Congress Squanders Opportunity to End the Disaster at the Border, Supports Status Quo Instead, Says FAIR

Retrieved on:

Sunday, October 1, 2023

House, Federation for American Immigration Reform, Failure, Senate, FY, Face, House of Representatives, Policy, Language, Nationality and Borders Act 2022, Congress, Federation, Continuing resolution, Representative, Democrat, CR, FAIR, Drug

WASHINGTON, Sept. 30, 2023 /PRNewswire/ -- "During this spending battle, the Republican-controlled House of Representatives squandered a chance to address one of the nation's most pressing crises—our dangerously out-of-control borders. The Continuing Resolution (CR), which was offered on the floor Friday, included many of the spending cuts conservative Republicans were demanding and it included strong policy changes that would have reversed the Biden administration's open-borders policies. Yet, nearly two dozen House Republicans voted against it.

Key Points:

In doing so, the Republicans who blocked Friday's CR proposal allowed the perfect to become the enemy of the good.
The status quo is not acceptable, and only policy changes will avert the crisis that the American people and communities across the country see today.
"Congress' failure to act in the face of this raging border crisis and humanitarian disaster is unconscionable.
"What took place over the last few days was a missed opportunity to address a full-fledged crisis.

EQS-News: KWS successfully concludes fiscal 2022/2023 and exceeds its sales and earnings guidance – Further growth anticipated

Retrieved on:

Wednesday, September 27, 2023

That was attributable to negative contributions to earnings from the joint ventures in North America and China, while earnings increased in Europe and Brazil.

Key Points:

That was attributable to negative contributions to earnings from the joint ventures in North America and China, while earnings increased in Europe and Brazil.
The strong expansion of business is attributable to the market success of innovative KWS varieties (CONVISO® SMART and CR+).
The segment’s income was €253.4 (195.0) million thanks to the positive net sales trend and was likewise significantly above the previous year’s figure.
Net sales in the Cereals Segment increased by 19.1% to €257.8 (216.4) million, mainly due to buoyant growth in oilseed rape, wheat and rye seed.

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

Retrieved on:

Tuesday, September 26, 2023

VANCOUVER, British Columbia, Sept. 26, 2023 /PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer among individuals younger than 55 years. Another study published in JAMA Network Open showed that early-onset cancer in people younger than 50 rose over the last decade, with gastrointestinal cancers seeing the fastest increase. This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now. Among the ongoing efforts that are drawing more attention in the pancreatic cancer space have been the developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Merus N.V. (NASDAQ: MRUS), Guardant Health, Inc. (NASDAQ: GH), Medtronic plc (NYSE: MDT), and even NVIDIA Corporation (NASDAQ: NVDA).

Key Points:

This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now.
"By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
Pelareorep delivered the company a big win near the end of 2022, when the FDA rewarded it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
"With a five-year survival rate of 12%, pancreatic cancer patients cannot afford to wait for new treatment options," said Julie Fleshman, JD, MBA, President and CEO of PanCAN.

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

Retrieved on:

Tuesday, September 26, 2023

VANCOUVER, British Columbia, Sept. 26, 2023 /PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer among individuals younger than 55 years. Another study published in JAMA Network Open showed that early-onset cancer in people younger than 50 rose over the last decade, with gastrointestinal cancers seeing the fastest increase. This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now. Among the ongoing efforts that are drawing more attention in the pancreatic cancer space have been the developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Merus N.V. (NASDAQ: MRUS), Guardant Health, Inc. (NASDAQ: GH), Medtronic plc (NYSE: MDT), and even NVIDIA Corporation (NASDAQ: NVDA).

Key Points:

This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now.
"By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
Pelareorep delivered the company a big win near the end of 2022, when the FDA rewarded it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
"With a five-year survival rate of 12%, pancreatic cancer patients cannot afford to wait for new treatment options," said Julie Fleshman, JD, MBA, President and CEO of PanCAN.

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Retrieved on:

Wednesday, September 20, 2023

American Urological Association, Cancer, CIS, BCG, Patient, Annual general meeting, CR, Rare, Therapy, Safety, Pharmaceutical industry, Vaccine, NMIBC

In addition, dosing is progressing in the ongoing ADVANCED-EXP trial started earlier this year with preliminary results expected in the first half of 2024.

Key Points:

In addition, dosing is progressing in the ongoing ADVANCED-EXP trial started earlier this year with preliminary results expected in the first half of 2024.
“There is significant need for new intravesical approaches for NMIBC, which can recur and progress to invasive disease with current treatments.
“Following positive preliminary results from the ADVANCED-1 trial, we are pleased to have dosed the first patient in the ADVANCED-2 trial,” said Jathin Bandari, M.D., Chief Medical Officer of Protara Therapeutics.
The ongoing ADVANCED-1EXP trial is a Phase 1b open-label expansion trial evaluating intravesical TARA-002 in 12 CIS patients, including BCG-naïve, BCG-unresponsive, and BCG-inadequately treated patients.

Aptose to Present at the Cantor Global Healthcare Conference

Retrieved on:

Monday, September 18, 2023

CRC, Failure, Symantec Endpoint Protection, TUS, CRH, Clinical trial, European School, AML, Patient, SAN, CR, CFO, CRi, TSX, FLT3, CRP, Conference, Venetoclax, Pharmaceutical industry

SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.

Key Points:

SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.
Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate on a panel, Targeted Therapies for AML, and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference.
To schedule a one-on-one meeting with the Aptose management team, please contact your conference representative.
Aptose expects to update these data and release data on additional evaluable patients next month during the European School of Haematology (ESH) meeting in Estoril, Portugal.